secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2026-09-02T11:22:04+00:00
Accession:  0001193125-26-379343
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 3.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan cuts 75% of workforce, pauses Phase 3 ALLOHA-2, refocuses on in vivo solid tumors
--------------------------------------------------------------------------------

- Workforce reduction ~75%; ~$4.1M employee-related costs; $55.0M cumulative savings through 2027; cash runway into Q4 2027.
- Pauses Phase 3 ALLOHA-2 enrollment of TSC-101; 7 patients on treatment arm; 13/13 Cohort C patients show complete donor chimerism.
- CFO Jason Amello and CMO Chrystal Louis terminated; CEO Gavin MacBeath assumes principal financial/accounting officer duties.
- Nasdaq minimum bid price deficiency notice Aug 27, 2026; must regain $1.00 compliance by Feb 23, 2027.
- Two in vivo TCR-T candidates (PRAME, MAGE-A4) advance to IND-enabling; IND Q3 2027, Phase 1 Q4 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/0001193125-26-379343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/d309786d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-379343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer